Moleculin Biotech, Inc. cash flow to debt ratio of -6.33K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Moleculin Biotech, Inc.'s free cash flow has increased -4.77% from $-23.88M last year to $-22.73M, signaling increasing performance

Moleculin Biotech, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Moleculin Biotech, Inc.'s debt has decreased relative to shareholder equity from 0.08 last year to 0.02 today, signaling strengthened financials

Moleculin Biotech, Inc. has negative EBITDA, making leverage ratio unreliable

Moleculin Biotech, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Moleculin Biotech, Inc. has insufficient data to evaluate this check.

Moleculin Biotech, Inc.'s short-term assets of $9.69M exceed its short-term liabilities of $6.85M

Moleculin Biotech, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Moleculin Biotech, Inc.'s return on equity of 3.11K%, is higher than 15.00%, indicating good performance

Moleculin Biotech, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Moleculin Biotech, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Moleculin Biotech, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Moleculin Biotech, Inc. has negative free cash flow, indicating cash burn

Moleculin Biotech, Inc.'s yearly earnings has decreased 54.21% since last year from $-21.76M to $-33.56M, signaling decreasing performance

Moleculin Biotech, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -173.94% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Moleculin Biotech, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Moleculin Biotech, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Moleculin Biotech, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Moleculin Biotech, Inc. has insufficient data to evaluate this check.

Moleculin Biotech, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Moleculin Biotech, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Moleculin Biotech, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Moleculin Biotech, Inc. has insufficient data to evaluate this check.

Moleculin Biotech, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Moleculin Biotech, Inc. has a price-to-book ratio of 0.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Moleculin Biotech, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue